Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Anti-cd33 antibodies and methods of use thereof
US2025270319A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2025270319-A1 |
| Application number | US-202519047214-A |
| Country | US |
| Kind code | A1 |
| Filing date | Feb 6, 2025 |
| Priority date | Aug 31, 2018 |
| Publication date | Aug 28, 2025 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
First claim
Opening claim text (preview).
1 .- 63 . (canceled) 64 . An isolated antibody that binds to CD33, wherein the antibody comprises a heavy chain variable comprising an HVR-H1, HVR-H2, and HVR-H3 and a light chain variable region comprising an HVR-L1, HVR-L2, and HVR-L3, wherein the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 8, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 9, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 54, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 9, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 9, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 55, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 10, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 11, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 12, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 13, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 14, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 15, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 16, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 17, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 18, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 19, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 20, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 21, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 22, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 23, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 24, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 25, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; the HVR-H1 comprises the amino acid sequence of SEQ ID
Assignees
Inventors
Classifications
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Constant or Fc region; Isotype · CPC title
multispecific · CPC title
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
comprising antibodies · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2025270319A1 cover?
- The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
- Who is the assignee on this patent?
- Alector Llc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2803. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Aug 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).